NMRA Phase 3 readout: a negative outcome, -6.6%

On May 15, 2026, NMRA-335140 — Neumora Therapeutics, Inc. (Major Depressive Disorder) reached its Phase 3 readout. The result was a negative outcome, and the stock moved -6.6% in the window around the event. It had already run -7.8% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.